(Q36734070)

16 August 2017

1 reference

title

Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease (English)

1 reference

16 August 2017

Paolo Ferrari

1

0 references

publication date

1 February 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

81-89

1 reference

Prevalence of kidney damage in Australian adults: The AusDiab kidney study.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Evolving strategies for renoprotection: diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

21 January 2018

Membranes for dialysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Insulin resistance and glomerular hemodynamics in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

Smoking as a risk factor for end-stage renal failure in men with primary renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00749.X

10.1111/J.1440-1797.2006.00749.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference